Annual EBITDA
-$215.26 M
+$670.21 M+75.69%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$215.26 million, with the most recent change of +$670.21 million (+75.69%) on 31 December 2023. During the last 3 years, it has risen by +$481.40 million (+69.10%). ALNY annual EBITDA is now -5042.50% below its all-time high of -$4.19 million, reached on 31 December 2002.ALNY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$47.25 M
-$94.03 M-201.00%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$47.25 million, with the most recent change of -$94.03 million (-201.00%) on 30 September 2024. Over the past year, it has dropped by -$252.41 million (-123.03%). ALNY quarterly EBITDA is now -123.03% below its all-time high of $205.17 million, reached on 30 September 2023.ALNY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$85.69 M
-$252.41 M-151.40%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$85.69 million, with the most recent change of -$252.41 million (-151.40%) on 30 September 2024. Over the past year, it has increased by +$199.42 million (+69.95%). ALNY TTM EBITDA is now -151.40% below its all-time high of $166.72 million, reached on 30 June 2024.ALNY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +75.7% | -123.0% | +70.0% |
| 3 y3 years | +69.1% | +66.4% | +86.0% |
| 5 y5 years | +71.1% | +75.8% | +88.3% |
ALNY EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +75.7% | -123.0% | +86.3% | -151.4% | +90.8% |
| 5 y | 5 years | at high | +75.7% | -123.0% | +86.3% | -151.4% | +90.8% |
| alltime | all time | -5042.5% | +75.7% | -123.0% | +86.3% | -151.4% | +90.8% |
Alnylam Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$47.25 M(-201.0%) | -$85.69 M(-151.4%) |
| June 2024 | - | $46.78 M(-1742.7%) | $166.72 M(-265.4%) |
| Mar 2024 | - | -$2.85 M(-96.5%) | -$100.78 M(-53.2%) |
| Dec 2023 | -$215.26 M(-75.7%) | -$82.38 M(-140.2%) | -$215.26 M(-24.5%) |
| Sept 2023 | - | $205.17 M(-193.0%) | -$285.11 M(-65.8%) |
| June 2023 | - | -$220.73 M(+88.1%) | -$834.49 M(+1.1%) |
| Mar 2023 | - | -$117.33 M(-22.9%) | -$825.59 M(-6.8%) |
| Dec 2022 | -$885.48 M(+43.0%) | -$152.22 M(-55.8%) | -$885.48 M(-5.3%) |
| Sept 2022 | - | -$344.21 M(+62.5%) | -$935.29 M(+27.8%) |
| June 2022 | - | -$211.83 M(+19.5%) | -$731.82 M(+13.9%) |
| Mar 2022 | - | -$177.22 M(-12.3%) | -$642.49 M(+3.7%) |
| Dec 2021 | -$619.43 M(-11.1%) | -$202.03 M(+43.5%) | -$619.43 M(+1.3%) |
| Sept 2021 | - | -$140.74 M(+14.9%) | -$611.60 M(-9.5%) |
| June 2021 | - | -$122.49 M(-20.5%) | -$675.80 M(-1.5%) |
| Mar 2021 | - | -$154.16 M(-20.6%) | -$686.19 M(-1.5%) |
| Dec 2020 | -$696.67 M(-16.2%) | -$194.20 M(-5.2%) | -$696.67 M(-8.8%) |
| Sept 2020 | - | -$204.95 M(+54.2%) | -$764.29 M(+1.2%) |
| June 2020 | - | -$132.88 M(-19.3%) | -$754.94 M(-8.9%) |
| Mar 2020 | - | -$164.64 M(-37.1%) | -$828.40 M(-1.2%) |
| Dec 2019 | -$830.88 M(+11.5%) | -$261.82 M(+33.9%) | -$838.45 M(+14.3%) |
| Sept 2019 | - | -$195.60 M(-5.2%) | -$733.56 M(-7.4%) |
| June 2019 | - | -$206.34 M(+18.1%) | -$792.12 M(+2.1%) |
| Mar 2019 | - | -$174.69 M(+11.3%) | -$775.89 M(+4.1%) |
| Dec 2018 | -$745.43 M(+52.7%) | -$156.93 M(-38.3%) | -$745.43 M(+1.6%) |
| Sept 2018 | - | -$254.15 M(+33.7%) | -$733.55 M(+21.9%) |
| June 2018 | - | -$190.12 M(+31.8%) | -$601.61 M(+13.7%) |
| Mar 2018 | - | -$144.23 M(-0.6%) | -$528.91 M(+8.3%) |
| Dec 2017 | -$488.19 M(+19.2%) | -$145.06 M(+18.7%) | -$488.19 M(+7.2%) |
| Sept 2017 | - | -$122.21 M(+4.1%) | -$455.55 M(+4.4%) |
| June 2017 | - | -$117.41 M(+13.4%) | -$436.51 M(+7.1%) |
| Mar 2017 | - | -$103.51 M(-7.9%) | -$407.54 M(-0.5%) |
| Dec 2016 | -$409.46 M(+47.8%) | -$112.42 M(+9.0%) | -$409.46 M(+6.5%) |
| Sept 2016 | - | -$103.18 M(+16.7%) | -$384.49 M(+8.5%) |
| June 2016 | - | -$88.44 M(-16.1%) | -$354.37 M(+6.1%) |
| Mar 2016 | - | -$105.43 M(+20.6%) | -$333.85 M(+20.5%) |
| Dec 2015 | -$276.96 M(+60.8%) | -$87.44 M(+19.7%) | -$276.96 M(+19.4%) |
| Sept 2015 | - | -$73.06 M(+7.6%) | -$231.89 M(+15.4%) |
| June 2015 | - | -$67.92 M(+40.0%) | -$200.91 M(+12.2%) |
| Mar 2015 | - | -$48.53 M(+14.5%) | -$179.01 M(+3.9%) |
| Dec 2014 | -$172.29 M(+108.3%) | -$42.37 M(+0.7%) | -$172.29 M(+9.8%) |
| Sept 2014 | - | -$42.08 M(-8.6%) | -$156.88 M(+8.7%) |
| June 2014 | - | -$46.03 M(+10.1%) | -$144.27 M(+23.5%) |
| Mar 2014 | - | -$41.81 M(+55.0%) | -$116.84 M(+41.3%) |
| Dec 2013 | -$82.71 M | -$26.96 M(-8.5%) | -$82.71 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | - | -$29.47 M(+58.4%) | -$77.08 M(+21.4%) |
| June 2013 | - | -$18.60 M(+142.3%) | -$63.47 M(+16.8%) |
| Mar 2013 | - | -$7.68 M(-64.0%) | -$54.33 M(-0.4%) |
| Dec 2012 | -$54.53 M(+9.7%) | -$21.33 M(+34.5%) | -$54.53 M(+19.7%) |
| Sept 2012 | - | -$15.86 M(+67.6%) | -$45.55 M(+11.5%) |
| June 2012 | - | -$9.46 M(+20.1%) | -$40.87 M(-5.5%) |
| Mar 2012 | - | -$7.88 M(-36.2%) | -$43.23 M(-13.0%) |
| Dec 2011 | -$49.69 M(+28.1%) | -$12.35 M(+10.5%) | -$49.69 M(+3.2%) |
| Sept 2011 | - | -$11.18 M(-5.5%) | -$48.13 M(+8.4%) |
| June 2011 | - | -$11.83 M(-17.5%) | -$44.42 M(+3.3%) |
| Mar 2011 | - | -$14.34 M(+32.9%) | -$42.99 M(+10.8%) |
| Dec 2010 | -$38.80 M(-5.4%) | -$10.79 M(+44.6%) | -$38.80 M(+14.7%) |
| Sept 2010 | - | -$7.46 M(-28.3%) | -$33.84 M(-3.1%) |
| June 2010 | - | -$10.40 M(+2.5%) | -$34.92 M(-22.4%) |
| Mar 2010 | - | -$10.14 M(+74.0%) | -$44.98 M(+9.7%) |
| Dec 2009 | -$41.02 M(+116.6%) | -$5.83 M(-31.7%) | -$41.02 M(+7.9%) |
| Sept 2009 | - | -$8.54 M(-58.3%) | -$38.02 M(+22.3%) |
| June 2009 | - | -$20.47 M(+231.3%) | -$31.09 M(+40.6%) |
| Mar 2009 | - | -$6.18 M(+117.7%) | -$22.10 M(+16.8%) |
| Dec 2008 | -$18.93 M(-74.8%) | -$2.84 M(+77.0%) | -$18.93 M(+368.0%) |
| Sept 2008 | - | -$1.60 M(-86.0%) | -$4.04 M(-92.3%) |
| June 2008 | - | -$11.48 M(+282.1%) | -$52.73 M(-4.6%) |
| Mar 2008 | - | -$3.01 M(-124.9%) | -$55.26 M(-26.4%) |
| Dec 2007 | -$75.06 M(+110.3%) | $12.05 M(-124.0%) | -$75.06 M(-21.8%) |
| Sept 2007 | - | -$50.29 M(+258.8%) | -$96.01 M(+83.0%) |
| June 2007 | - | -$14.02 M(-38.5%) | -$52.47 M(+6.1%) |
| Mar 2007 | - | -$22.80 M(+156.1%) | -$49.48 M(+38.6%) |
| Dec 2006 | -$35.69 M(-11.6%) | -$8.90 M(+31.9%) | -$35.69 M(-12.8%) |
| Sept 2006 | - | -$6.75 M(-38.7%) | -$40.95 M(-7.2%) |
| June 2006 | - | -$11.02 M(+22.3%) | -$44.12 M(+1.8%) |
| Mar 2006 | - | -$9.01 M(-36.4%) | -$43.35 M(+7.4%) |
| Dec 2005 | -$40.35 M(+35.3%) | -$14.16 M(+42.6%) | -$40.35 M(+30.3%) |
| Sept 2005 | - | -$9.93 M(-3.1%) | -$30.97 M(+15.8%) |
| June 2005 | - | -$10.25 M(+70.7%) | -$26.74 M(+16.2%) |
| Mar 2005 | - | -$6.01 M(+25.6%) | -$23.00 M(-22.9%) |
| Dec 2004 | -$29.82 M(+52.1%) | -$4.78 M(-16.1%) | -$29.82 M(-34.6%) |
| Sept 2004 | - | -$5.70 M(-12.6%) | -$45.62 M(+14.4%) |
| June 2004 | - | -$6.52 M(-49.1%) | -$39.88 M(+13.5%) |
| Mar 2004 | - | -$12.82 M(-37.7%) | -$35.14 M(+49.0%) |
| Dec 2003 | -$19.61 M(+368.5%) | -$20.58 M(<-9900.0%) | -$23.59 M(+684.6%) |
| Sept 2003 | - | $44.00 K(-102.5%) | -$3.01 M(-1.4%) |
| June 2003 | - | -$1.78 M(+40.9%) | -$3.05 M(+140.9%) |
| Mar 2003 | - | -$1.27 M | -$1.27 M |
| Dec 2002 | -$4.19 M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual EBITDA year-on-year change?
- What is Alnylam Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Alnylam Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM EBITDA year-on-year change?
What is Alnylam Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ALNY is -$215.26 M
What is the all time high annual EBITDA for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$4.19 M
What is Alnylam Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ALNY annual earnings before interest, taxes, depreciation & amortization has changed by +$670.21 M (+75.69%)
What is Alnylam Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ALNY is -$47.25 M
What is the all time high quarterly EBITDA for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $205.17 M
What is Alnylam Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ALNY quarterly earnings before interest, taxes, depreciation & amortization has changed by -$252.41 M (-123.03%)
What is Alnylam Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ALNY is -$85.69 M
What is the all time high TTM EBITDA for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $166.72 M
What is Alnylam Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ALNY TTM earnings before interest, taxes, depreciation & amortization has changed by +$199.42 M (+69.95%)